Biotech Startups

Index Biosystems builds an AI platform for food safety and quality assurance (FSQA) teams in food manufacturing, combining AI agents that automate investigations and audit prep with BioTags — food-grade, DNA-labeled microbial tracers that generate molecular data for tracing material movement and validating sanitation. The platform maps facilities, SOPs, and testing programs into a knowledge graph so agents can reason about operations and shift food safety programs from reactive to predictive.

4 investors

Infinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.

4 investors

Infinite Roots cultivates mycelium (mushroom roots) via liquid fermentation using natural side streams such as brewers' spent grain, turning it into protein-, fiber-, and vitamin-rich culinary ingredients. The company operates in the alternative protein and sustainable foodtech category, producing meat and food alternatives for consumer meals and dining.

4 investors

Inflow is an app-based program providing personalized coaching, strategies, and tools to help people with ADHD manage their condition. The platform combines clinical guidance from psychology experts with a supportive community, designed to make mental health support affordable and accessible for neurodiverse individuals.

4 investors

Ingrediome produces meat and fish made from real muscle proteins, using sunlight and CO2 captured from the air to create nature-identical products decoupled from animal agriculture. It targets meat consumers seeking healthier and more sustainable alternatives with the taste and texture of traditional meat.

4 investors

Inhalon Biopharma is a clinical-stage biotechnology company developing inhaled "muco-trapping" antibody treatments for acute respiratory infections, including RSV, influenza, human metapneumovirus, and SARS-CoV-2. Its therapies aim to treat active infection directly in the lung.

4 investors

Inhibrx develops protein therapeutics, using target biology and protein engineering to create therapeutic candidates in clinical trials for conditions including sarcoma and head and neck cancer. The company operates in the biotherapeutics and drug development industry.

4 investors

InnoVein develops a replacement valve for veins intended to treat chronic, hard-to-heal leg wounds. The company works in the medical device field addressing venous insufficiency.

4 investors

InsituGen develops cell-free bioassay technology for steroid hormone testing, offering a low-cost test to detect androgen and estrogen bioactivity in companion animal diagnostics. Its products include equine anti-doping and companion animal diagnostic tests, serving the animal health and diagnostics markets.

4 investors

Commercializing rapid DNA analysis technology for forensics; acquired by Thermo Fisher Scientific in 2018.

4 investors

Intercept Pharmaceuticals develops and commercializes treatments for rare and serious liver and other diseases, with a focus on conditions such as primary biliary cholangitis. The page displays corporate news related to Alfasigma, its parent/affiliated pharmaceutical company.

4 investors

Interface Bio develops immunotherapies targeting complex inflammatory diseases by combining biological evolution, metabolomics, and machine learning to discover natural-derived therapeutic products.

4 investors

Interobio Systems develops stem-cell-derived human intestinal organoids that include functioning neurons, blood vessels, muscle, and intestinal lining for use in preclinical drug testing. The company applies human biology and organoid technology to support drug discovery and development.

4 investors

InventisBio is a China-based drug discovery company developing patent-protected small-molecule targeted therapies for oncology and metabolic diseases. Its pipeline addresses solid tumors such as non-small cell lung, breast, and colorectal cancer, as well as hyperuricemia/gout and autoimmune conditions like psoriasis.

4 investors

Invirsa is a clinical-stage biopharmaceutical company developing DNA damage response therapeutics, with lead compound INV-102 in development for ocular conditions including sulfur mustard gas injury and diabetic dry eye disease.

4 investors

IrisMed is an AI-powered software platform that automates insurance verification and patient cost estimation for optical practices, integrating with existing practice management systems. It helps dispensaries determine accurate patient out-of-pocket costs for lenses, coatings, and frames while identifying upsell opportunities.

4 investors

Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases. It concentrates on GI drug discovery and care for patients suffering from digestive diseases.

4 investors

Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases. The company is running clinical studies in chronic spontaneous urticaria, chronic inducible urticaria, and allergic asthma.

4 investors

Jazz Pharmaceuticals is a biopharmaceutical company developing treatments for rare diseases and cancers, with a focus on oncology and biomarker-driven therapies such as those targeting HER2-expressing cancers. It serves patients with high unmet medical needs in rare disease and rare cancer areas.

4 investors

Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins. The platform uses proprietary reactive affinity probes and high-throughput screening to accelerate drug discovery across challenging target classes including transporters, transcription factors, and GPCRs.

4 investors

Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform. The company applies RNA-based therapeutics that harness a natural endogenous mechanism for receptor-mediated uptake by specific kidney cell types to silence disease-modifying genes.

4 investors

Jumpcode Genomics develops CRISPRclean, a next-generation sequencing technology that removes abundant, uninformative sequences to improve sensitivity, lower costs, and simplify workflows for researchers. Its technology is used in basic research, infectious disease, oncology, and consumer genomics.

4 investors

A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.

4 investors

Kallyope is a biotechnology company founded by neuroscientists that discovers and develops novel therapeutics targeting neural networks, with a lead candidate in pivotal studies for acute migraine treatment and metabolism programs approaching clinical studies. It applies its integrated discovery platform to develop drugs for challenging diseases.

4 investors